Mucus-penetrating nonviral gene vaccine processed in the epithelium for inducing advanced vaginal mucosal immune responses

Bi, Qunjie; Xu, Song; Zhao, Yangyang; Hu, Xueyi; Yang, Huan; Jin, Rongrong; Nie, Yu

doi:10.1016/j.apsb.2022.11.004

Cited by 4 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…186 Among these, chitosan stands out due to its nontoxicity, excellent biocompatibility and mucosal adhesion properties, and absorption enhancement 187 (Figure 9E). Recently, Bi et al 188 counted two nonviral nanocarriers with different charge-reversal properties (DRLS) to simultaneously overcome the barrier and induce an immune response. DRLS applied for intravaginal immunization induced high IgA levels compared to intramuscular injection of DNA (naked), indicating timely protection against pathogens in the mucus layer.…”

Section: Mucosal Immunitymentioning

confidence: 99%

DNA-Based Nonviral Gene Therapy─Challenging but Promising

Guan,

Pei,

Song

2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Over the past decades, significant progress has been made in utilizing nucleic acids, including DNA and RNA molecules, for therapeutic purposes. For DNA molecules, although various DNA delivery systems have been established, viral vector systems are the go-to choice for large-scale commercial applications. However, viral systems have certain disadvantages such as immune response, limited payload capacity, insertional mutagenesis and pre-existing immunity. In contrast, nonviral systems are less immunogenic, not size limited, safer, and easier for manufacturing compared with viral systems. What's more, nonviral DNA vectors have demonstrated their capacity to mediate specific protein expression in vivo for diverse therapeutic objectives containing a wide range of diseases such as cancer, rare diseases, neurodegenerative diseases, and infectious diseases, yielding promising therapeutic outcomes. However, exogenous plasmid DNA is prone to degrade and has poor immunogenicity in vivo. Thus, various strategies have been developed: (i) designing novel plasmids with special structures, (ii) optimizing plasmid sequences for higher expression, and (iii) developing more efficient nonviral DNA delivery systems. Based on these strategies, many interesting clinical results have been reported. This Review discusses the development of DNA-based nonviral gene therapy, including novel plasmids, nonviral delivery systems, clinical advances, and prospects. These developments hold great potential for enhancing the efficacy and safety of nonviral gene therapy and expanding its applications in the treatment of various diseases.

show abstract

Section: Mucosal Immunitymentioning

confidence: 99%